223 related articles for article (PubMed ID: 37899716)
1. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
[TBL] [Abstract][Full Text] [Related]
2. Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
Bakouni H; McAnulty C; Tatar O; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
Am J Addict; 2023 Sep; 32(5):469-478. PubMed ID: 37308805
[TBL] [Abstract][Full Text] [Related]
3. Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study.
Bakouni H; Haquet L; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
J Addict Med; 2024 Mar-Apr 01; 18(2):167-173. PubMed ID: 38258865
[TBL] [Abstract][Full Text] [Related]
4. Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
Bastien G; McAnulty C; Ledjiar O; Socias ME; Le Foll B; Lim R; Hassan AN; Brissette S; Marsan S; Talbot A; Jutras-Aswad D;
Can J Psychiatry; 2023 Aug; 68(8):572-585. PubMed ID: 36519188
[TBL] [Abstract][Full Text] [Related]
5. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study.
Elkrief L; Bastien G; McAnulty C; Bakouni H; Hébert FO; Socias ME; Le Foll B; Lim R; Ledjiar O; Marsan S; Brissette S; Jutras-Aswad D;
J Subst Use Addict Treat; 2023 Jun; 149():209031. PubMed ID: 37003540
[TBL] [Abstract][Full Text] [Related]
7. The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial.
Bahji A; Bastien G; Bach P; Choi J; Le Foll B; Lim R; Jutras-Aswad D; Socias ME
Can J Psychiatry; 2024 Mar; 69(3):172-182. PubMed ID: 37697811
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder.
Enns B; Krebs E; Whitehurst DGT; Jutras-Aswad D; Le Foll B; Socias ME; Nosyk B;
Drug Alcohol Depend; 2023 Jun; 247():109893. PubMed ID: 37120920
[TBL] [Abstract][Full Text] [Related]
9. Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences.
Wang K; Shafique S; Xiao D; Walter SM; Liu Y; Piamjariyakul U; Xie C
J Addict Dis; 2024; 42(1):33-44. PubMed ID: 36655851
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.
McAnulty C; Bastien G; Eugenia Socias M; Bruneau J; Foll BL; Lim R; Brissette S; Ledjiar O; Marsan S; Talbot A; Jutras-Aswad D;
Drug Alcohol Depend; 2022 Oct; 239():109604. PubMed ID: 36037586
[TBL] [Abstract][Full Text] [Related]
11. Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial.
McAnulty C; Bastien G; Ledjiar O; Eugenia Socias M; Le Foll B; Lim R; Jutras-Aswad D;
Addict Behav; 2024 Jul; 154():108023. PubMed ID: 38579594
[TBL] [Abstract][Full Text] [Related]
12. Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization.
Skains RM; Reynolds L; Carlisle N; Heath S; Covington W; Hornbuckle K; Walter L
West J Emerg Med; 2023 Nov; 24(6):1010-1017. PubMed ID: 38165181
[TBL] [Abstract][Full Text] [Related]
13. [Directive clinique n
Turner S; Allen VM; Carson G; Graves L; Tanguay R; Green CR; Cook JL
J Obstet Gynaecol Can; 2023 Nov; 45(11):102146. PubMed ID: 37977719
[TBL] [Abstract][Full Text] [Related]
14. Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial.
Bastien G; Abboud A; McAnulty C; Elkrief L; Ledjiar O; Socias ME; Le Foll B; Bahji A; Brissette S; Marsan S; Jutras-Aswad D
J Dual Diagn; 2024; 20(3):189-200. PubMed ID: 38580298
[TBL] [Abstract][Full Text] [Related]
15. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.
Nielsen S; Hillhouse M; Weiss RD; Mooney L; Sharpe Potter J; Lee J; Gourevitch MN; Ling W
Am J Addict; 2014; 23(4):343-8. PubMed ID: 24112096
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.
Lucas GM; Young A; Donnell D; Richardson P; Aramrattana A; Shao Y; Ruan Y; Liu W; Fu L; Ma J; Celentano DD; Metzger D; Jackson JB; Burns D;
Drug Alcohol Depend; 2014 Sep; 142():139-45. PubMed ID: 24999060
[TBL] [Abstract][Full Text] [Related]
17. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone.
Kazi I; Chenoweth MJ; Jutras-Aswad D; Ahamad K; Socias ME; Le Foll B; Tyndale RF
Clin Pharmacol Ther; 2024 Mar; 115(3):506-514. PubMed ID: 38009933
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
[TBL] [Abstract][Full Text] [Related]
20. Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada.
Iacono A; Wang T; Tadrous M; Campbell T; Kolla G; Leece P; Sproule B; Kleinman RA; Besharah J; Munro C; Doolittle M; Gomes T
Drug Alcohol Depend; 2024 Jan; 254():111032. PubMed ID: 38043224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
